GRENOBLE, France--(BUSINESS WIRE)--PX’Therapeutics is pleased to announce the launching of a Phase 1 clinical trial of a prophylactic vaccine against HIV entitled: “Phase 1, Randomised, Single-centre, Observer-blind Clinical Trial of Safety and Immunogenicity of Nasal-prime and Intramuscular Boost Immunisation With EN41-FPA2 HIV Vaccine in Healthy Female Volunteers.”
